Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens.

Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Cheng HH, Tagawa ST, Appleman LJ, Tutrone R, Garcia JA, Whang YE, Kelly WK, Weiner DB, Bagarazzi ML, Skolnik JM.

Mol Ther. 2020 Mar 3. pii: S1525-0016(20)30134-9. doi: 10.1016/j.ymthe.2020.02.018. [Epub ahead of print]

PMID:
32208168
2.

PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.

Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ.

Prostate. 2020 Jan;80(1):99-108. doi: 10.1002/pros.23922. Epub 2019 Nov 19.

PMID:
31742767
3.

Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.

Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, Swartz L, Owonikoko TK, Donald Harvey R, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Pouquet M, Kiesel B, Chen AP, Gandara D, Belani CP, Chu E, Ramalingam SS.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1289-1301. doi: 10.1007/s00280-019-03960-w. Epub 2019 Sep 23.

PMID:
31549216
4.

Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.

Luu T, Frankel P, Beumer JH, Lim D, Cristea M, Appleman LJ, Lenz HJ, Gandara DR, Kiesel BF, Piekarz RL, Newman EM.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1201-1208. doi: 10.1007/s00280-019-03955-7. Epub 2019 Sep 14.

PMID:
31522242
5.

Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium.

Russell KL, Gorgulho CM, Allen A, Vakaki M, Wang Y, Facciabene A, Lee D, Roy P, Buchser WJ, Appleman LJ, Maranchie J, Storkus WJ, Lotze MT.

Cancer J. 2019 May/Jun;25(3):165-177. doi: 10.1097/PPO.0000000000000374.

PMID:
31135523
6.

Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients.

Alevizakos M, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ.

Clin Genitourin Cancer. 2019 Jun;17(3):e447-e453. doi: 10.1016/j.clgc.2019.01.005. Epub 2019 Jan 17.

PMID:
30799129
7.

Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.

Haas NB, Appleman LJ, Stein M, Redlinger M, Wilks M, Xu X, Onorati A, Kalavacharla A, Kim T, Zhen CJ, Kadri S, Segal JP, Gimotty PA, Davis LE, Amaravadi RK.

Clin Cancer Res. 2019 Apr 1;25(7):2080-2087. doi: 10.1158/1078-0432.CCR-18-2204. Epub 2019 Jan 11.

8.

Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries With Bladder Cancer: A SEER-Medicare Analysis.

Hugar LA, Yabes JG, Turner RM 2nd, Fam MM, Appleman LJ, Davies BJ, Jacobs BL.

Urology. 2019 Feb;124:191-197. doi: 10.1016/j.urology.2018.11.001. Epub 2018 Nov 10.

PMID:
30423302
9.

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI.

J Immunother Cancer. 2018 Jan 29;6(1):9. doi: 10.1186/s40425-018-0319-9.

10.

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.

Escudier B, Powles T, Motzer RJ, Olencki T, Arén Frontera O, Oudard S, Rolland F, Tomczak P, Castellano D, Appleman LJ, Drabkin H, Vaena D, Milwee S, Youkstetter J, Lougheed JC, Bracarda S, Choueiri TK.

J Clin Oncol. 2018 Mar 10;36(8):765-772. doi: 10.1200/JCO.2017.74.7352. Epub 2018 Jan 8.

11.

High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features.

Achkar T, Arjunan A, Wang H, Saul M, Davar D, Appleman LJ, Friedland D, Parikh RA.

PLoS One. 2017 Dec 20;12(12):e0190084. doi: 10.1371/journal.pone.0190084. eCollection 2017.

12.

Primary Urinary Tract Lymphoma: Rare but Aggressive.

Lontos K, Tsagianni A, Msaouel P, Appleman LJ, Nasioudis D.

Anticancer Res. 2017 Dec;37(12):6989-6995.

13.

Systemic therapy following metastasectomy for renal cell carcinoma: Using insights from other clinical settings to address unanswered questions.

Appleman LJ, Maranchie JK.

Urol Oncol. 2018 Jan;36(1):17-22. doi: 10.1016/j.urolonc.2017.06.005. Epub 2017 Jul 20. Review.

PMID:
28736252
14.

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.

de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK.

Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20.

15.

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation.

Nguyen NC, Shah M, Appleman LJ, Parikh R, Mountz JM.

Int J Mol Imaging. 2016;2016:2568031. Epub 2016 Sep 27. Review.

16.

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Peña C, Xia C, Reif S, Genvresse I, Ramanathan RK.

Ann Oncol. 2016 Oct;27(10):1928-40. doi: 10.1093/annonc/mdw282.

17.

Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups.

de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen EM, Choueiri TK.

Cancer Immunol Res. 2016 Oct;4(10):820-822. Epub 2016 Aug 18.

18.

Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Practical Clinical Implications of Pharmacologic Features.

Parikh RA, Appleman LJ, Beumer JH, Matczak E, Chu E.

Clin Genitourin Cancer. 2017 Feb;15(1):7-22. doi: 10.1016/j.clgc.2016.05.011. Epub 2016 May 31. Review.

PMID:
27473523
19.

Broccoli-Derived Sulforaphane and Chemoprevention of Prostate Cancer: From Bench to Bedside.

Amjad AI, Parikh RA, Appleman LJ, Hahm ER, Singh K, Singh SV.

Curr Pharmacol Rep. 2015 Nov 1;1(6):382-390. Epub 2015 Apr 16.

20.

A phase i study of DMS612, a novel bifunctional alkylating agent.

Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE.

Clin Cancer Res. 2015 Feb 15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. Epub 2014 Dec 2.

21.

Renal medullary carcinoma: case report of an aggressive malignancy with near-complete response to dose-dense methotrexate, vinblastine, Doxorubicin, and Cisplatin chemotherapy.

Amjad AI, Ali H, Appleman LJ, Maranchie J, Jackman S, Parwani A, Dhir R, Roy S, Parikh RA.

Case Rep Oncol Med. 2014;2014:615895. doi: 10.1155/2014/615895. Epub 2014 Aug 19.

22.

The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.

Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ.

Onco Targets Ther. 2014 Jun 11;7:969-83. doi: 10.2147/OTT.S40241. eCollection 2014. Review.

23.

Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.

Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE.

J Clin Oncol. 2014 Jun 20;32(18):1889-94. doi: 10.1200/JCO.2013.52.4785. Epub 2014 May 12.

24.

A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.

Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ.

Clin Genitourin Cancer. 2014 Jun;12(3):167-177.e2. doi: 10.1016/j.clgc.2013.11.007. Epub 2013 Nov 13.

25.

Upregulation of the ATR-CHEK1 pathway in oral squamous cell carcinomas.

Parikh RA, Appleman LJ, Bauman JE, Sankunny M, Lewis DW, Vlad A, Gollin SM.

Genes Chromosomes Cancer. 2014 Jan;53(1):25-37. doi: 10.1002/gcc.22115. Epub 2013 Oct 21.

26.

DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature.

Chi Sabins N, Taylor JL, Fabian KP, Appleman LJ, Maranchie JK, Stolz DB, Storkus WJ.

Mol Ther. 2013 Oct;21(10):1958-68. doi: 10.1038/mt.2013.133. Epub 2013 Jul 30.

27.

Clinical problem-solving. Simple and complex.

Leng S, Nallamothu BK, Saint S, Appleman LJ, Bump GM.

N Engl J Med. 2013 Jan 3;368(1):65-71. doi: 10.1056/NEJMcps1202256. No abstract available.

PMID:
23281978
28.

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.

Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen J, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD.

Eur J Cancer. 2011 Dec;47(18):2706-14. doi: 10.1016/j.ejca.2011.09.002. Epub 2011 Nov 10.

29.

MET signaling pathway: a rational target for cancer therapy.

Appleman LJ.

J Clin Oncol. 2011 Dec 20;29(36):4837-8. doi: 10.1200/JCO.2011.37.7929. Epub 2011 Oct 31. No abstract available.

PMID:
22042966
30.

Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.

Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ, Stoller RG, Grandis JR, Egloff AM.

Invest New Drugs. 2012 Aug;30(4):1575-84. doi: 10.1007/s10637-011-9732-3. Epub 2011 Sep 1.

31.

Castration-refractory prostate cancer: new therapies, new questions.

Appleman LJ.

Oncology (Williston Park). 2010 Dec;24(14):1318-9, 1326. No abstract available.

32.

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.

Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, Sundaresan PR.

Cancer Chemother Pharmacol. 2011 Apr;67(4):751-64. doi: 10.1007/s00280-010-1372-3. Epub 2010 Jun 3.

33.

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum S, Heath EI, Boerner SA, LoRusso PM.

Clin Cancer Res. 2010 Jul 1;16(13):3507-16. doi: 10.1158/1078-0432.CCR-10-0574. Epub 2010 May 14.

34.

Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology.

Im A, Appleman LJ.

Expert Opin Pharmacother. 2010 Feb;11(3):481-8. doi: 10.1517/14656560903535880. Review.

PMID:
20102310
35.

Pharmacologic administration of interleukin-2.

Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT.

Ann N Y Acad Sci. 2009 Dec;1182:14-27. doi: 10.1111/j.1749-6632.2009.05160.x.

PMID:
20074271
36.

Update on vaccine development for renal cell cancer.

Chi N, Maranchie JK, Appleman LJ, Storkus WJ.

Open Access J Urol. 2010 Aug 4;2:125-41. Review.

37.

In vitro models of human T cell anergy.

Appleman LJ, Boussiotis V.

Curr Protoc Immunol. 2005 Mar;Chapter 7:Unit 7.36. doi: 10.1002/0471142735.im0736s65.

PMID:
18432957
38.

A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.

Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JC Jr.

Cancer. 2006 Dec 1;107(11):2688-97.

39.

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.

Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J Jr, Eder JP.

Cancer. 2006 Nov 15;107(10):2482-9.

40.
41.

Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.

George S, Desai J, Paul Eder J, Manola J, Ryan DP, Appleman LJ, Demetri GD.

Eur J Cancer. 2006 May;42(7):864-70. Epub 2006 Feb 28.

PMID:
16503137
42.

Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.

Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP Jr.

Clin Cancer Res. 2005 Nov 1;11(21):7825-33.

43.

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.

Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP.

Br J Cancer. 2005 Jul 11;93(1):54-9.

44.

Differential localization and function of ADP-ribosylation factor-6 in anergic human T cells: a potential marker for their identification.

Tzachanis D, Appleman LJ, Van Puijenbroek AA, Berezovskaya A, Nadler LM, Boussiotis VA.

J Immunol. 2003 Aug 15;171(4):1691-6.

45.

T cell anergy and costimulation.

Appleman LJ, Boussiotis VA.

Immunol Rev. 2003 Apr;192:161-80. Review.

PMID:
12670403
46.

Induction of immunologic tolerance for allogeneic hematopoietic cell transplantation.

Appleman LJ, Tzachanis D, Grader-Beck T, Van Puijenbroek AA, Boussiotis VA.

Leuk Lymphoma. 2002 Jun;43(6):1159-67. Review.

PMID:
12152983
47.
48.

Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics.

Appleman LJ, Tzachanis D, Grader-Beck T, van Puijenbroek AA, Boussiotis VA.

J Mol Med (Berl). 2001;78(12):673-83. Review.

PMID:
11434720
49.

Sexuality and cancer: conversation comfort zone.

Penson RT, Gallagher J, Gioiella ME, Wallace M, Borden K, Duska LA, Talcott JA, McGovern FJ, Appleman LJ, Chabner BA, Lynch TJ Jr.

Oncologist. 2000;5(4):336-44.

50.

CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression.

Appleman LJ, Berezovskaya A, Grass I, Boussiotis VA.

J Immunol. 2000 Jan 1;164(1):144-51.

Supplemental Content

Loading ...
Support Center